Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule

Table 2 Inhibition of the growth of mouse hepatoma 22 by LDM and MMC

Experiment Groups		Dose(mg/kg)	Ivtimes	Number of mice		Body weight (g)		Tumorweight (g)	Inhibitionrate (%)	P
				Begin	End	Begin	End
I	Control		1	10	10	19.6	35	4.19 ± 1.36	---	---
	LDM	0.1	1	10	10	20.2	26.5	0.64 ± 0.17	84.7	< 0.01
		0.05	1	10	10	19.6	27.5	1.19 ± 0.50	71.6	< 0.01
		0.025	1	10	10	19.9	30.3	1.60 ± 0.61	61.8	< 0.01
		0.0125	1	10	10	19.5	30.7	1.65 ± 0.50	60.6	< 0.01
		0.00625	1	10	10	19.9	31.5	2.48 ± 0.78	40.8	< 0.01
	MMC	5	1	10	10	19.8	32.3	1.72 ± 0.40	58.9	< 0.01
		2.5	1	10	10	19.9	31.5	2.10 ± 0.84	49.9	< 0.01
		1.25	1	10	10	20	33.4	2.34 ± 0.83	44.2	< 0.01
II	Control		2	10	10	20.2	35.2	3.83 ± 1.22	---	---
	LDM	0.1	2	10	10	20.2	23.5	0.43 ± 0.16	88.8	< 0.01
		0.05	2	10	10	19.7	26.6	0.67 ± 0.20	82.5	< 0.01
		0.025	2	10	10	20.1	29.6	0.96 ± 0.30	74.9	< 0.01
		0.0125	2	10	10	20.3	32.8	1.55 ± 0.63	59.5	< 0.01
		0.00625	2	10	10	20	31.9	1.98 ± 0.77	48.3	< 0.01
	MMC	5	2	10	9	19.6	23.9	1.01 ± 0.29	73.6	< 0.01
		2.5	2	10	10	20.2	30.2	1.76 ± 0.76	54	< 0.01
		1.25	2	10	10	20.3	33.8	1.83 ± 0.48	52.2	< 0.01
III	Control		2	10	10	19.2	28.9	3.33 ± 1.04	---	---
	LDM	0.1	2	10	10	19.7	20.2	0.35 ± 0.06	89.5	< 0.01
		0.05	2	10	10	19.8	25.2	0.63 ± 0.23	81.1	< 0.01
		0.025	2	10	10	19.2	23.7	0.96 ± 0.45	71.2	< 0.01
		0.0125	2	10	10	19.4	27.8	1.59 ± 0.72	52.3	< 0.01
		0.00625	2	10	10	19.6	26.6	2.22 ± 0.81	33.3	< 0.05
	MMC	5	2	10	10	19.8	25.1	1.08 ± 0.59	67.6	< 0.01
		2.5	2	10	10	19.6	25.1	1.45 ± 0.88	56.5	< 0.01
		1.25	2	10	10	19.6	28.1	2.28 ± 0.96	31.5	< 0.05